President and CEO
Mark Feinberg, M.D., Ph.D., is president and CEO of IAVI where he leads a global team working to advance the development of vaccines and other biomedical innovations to protect against infection with HIV, TB, and other infectious diseases that disproportionately impact low-income countries.
Prior to joining IAVI in late 2015, Feinberg served as chief public health and science officer with Merck Vaccines. In this role, he helped advance the development and global availability of vaccines against rotavirus, human papillomavirus, and other infectious diseases. He also led a range of research initiatives to address unmet health needs in low-income countries including the establishment of the MSD-Wellcome Trust Hilleman Laboratories and the coordination of a private-public partnership to expedite Ebola vaccine development. Previously, he spent more than 20 years exploring HIV/AIDS pathogenesis, treatment, and prevention research and the biology of emerging diseases in both academia and government.
Feinberg holds an M.D. and a Ph.D. from Stanford University, and B.A. degree from the University of Pennsylvania. He pursued post-graduate medical training in internal medicine at the Brigham and Women’s Hospital and postdoctoral fellowship training in the laboratory of Dr. David Baltimore at the Whitehead Institute. He has previously served as a faculty member at the University of California, San Francisco and the Emory University School of Medicine and as a medical officer in the Office of AIDS Research at the National Institutes of Health (NIH) and as a fellow in the Advanced Leadership Initiative at Harvard University.
Feinberg is a fellow of the American College of Physicians and a member of the Council on Foreign Relations and the Association of American Physicians. He served as the chair of the Interim Scientific Advisory Committee of the Collaboration for Epidemic Preparedness Innovations (CEPI) and currently serves as a member of the CEPI Joint Coordinating Group.